Merck releases new data on Keytruda® (pembrolizumab) in combination with Lenvima® (levatinib)

Jun 7, 2021

Merck released new data on Keytruda® (pembrolizumab) in combination with Lenvima® (levatinib) versus sunitinib in patients with advanced renal cancer. Merck said that the results reinforced the combination of pembrolizumab and levatinib as a potential new treatment option for renal cancer.

Print Page Mail Article